GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Cyclically Adjusted Revenue per Share

WAVE Life Sciences (WAVE Life Sciences) Cyclically Adjusted Revenue per Share : $0.50 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

WAVE Life Sciences's adjusted revenue per share for the three months ended in Dec. 2023 was $0.262. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.50 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-28), WAVE Life Sciences's current stock price is $4.66. WAVE Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.50. WAVE Life Sciences's Cyclically Adjusted PS Ratio of today is 9.32.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of WAVE Life Sciences was 13.56. The lowest was 7.82. And the median was 9.88.


WAVE Life Sciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for WAVE Life Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Cyclically Adjusted Revenue per Share Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.50

WAVE Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.50

Competitive Comparison of WAVE Life Sciences's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, WAVE Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Cyclically Adjusted PS Ratio falls into.



WAVE Life Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, WAVE Life Sciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.262/129.4194*129.4194
=0.262

Current CPI (Dec. 2023) = 129.4194.

WAVE Life Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.001 99.621 0.001
201506 0.006 100.684 0.008
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.018 101.688 0.023
201609 0.017 101.861 0.022
201612 0.012 101.863 0.015
201703 0.016 102.862 0.020
201706 0.041 103.349 0.051
201709 0.047 104.136 0.058
201712 0.039 104.011 0.049
201803 0.051 105.290 0.063
201806 0.167 106.317 0.203
201809 0.153 106.507 0.186
201812 0.123 105.998 0.150
201903 0.093 107.251 0.112
201906 0.223 108.070 0.267
201909 0.085 108.329 0.102
201912 0.070 108.420 0.084
202003 0.121 108.902 0.144
202006 0.086 108.767 0.102
202009 0.090 109.815 0.106
202012 0.193 109.897 0.227
202103 0.000 111.754 0.000
202106 0.056 114.631 0.063
202109 0.718 115.734 0.803
202112 0.031 117.630 0.034
202203 0.029 121.301 0.031
202206 0.006 125.017 0.006
202209 0.003 125.227 0.003
202212 0.013 125.222 0.013
202303 0.127 127.348 0.129
202306 0.210 128.729 0.211
202309 0.460 129.860 0.458
202312 0.262 129.419 0.262

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


WAVE Life Sciences  (NAS:WVE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

WAVE Life Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.66/0.5
=9.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of WAVE Life Sciences was 13.56. The lowest was 7.82. And the median was 9.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


WAVE Life Sciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences (WAVE Life Sciences) Business Description

Industry
Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
Executives
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kyle Moran officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chandra Vargeese officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Paul Bolno director, officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A. Panzara officer: Franchise Lead, Neurology 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero officer: Interim CFO 733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan director